Date:04/06/2006 URL: http://www.thehindubusinessline.com/2006/06/04/stories/2006060403120300.htm

Back Ranbaxy to sell Doxycycline in US

Our Bureau

New Delhi, June 3

Ranbaxy Laboratories Ltd has announced that the company has received approval from the US Food and Drug Administration (FDA) to manufacture and market Doxycycline Tablets — 50 mg, 75 mg, and 100 mg in the US market. The Office of Generic Drugs, FDA has determined the Ranbaxy formulation to be bio-equivalent and have the same therapeutic effect as that of the branded drug Adoxa, marketed by Bioglan Pharmaceutical Co. Annualised market sales for Adoxa were $57.2 million of the Doxycycline market, which achieved sales of $62.7 million (IMS - MAT: March 2006). Doxycycline is indicated for a variety of infections caused by susceptible strains of micro-organisms including respiratory tract and urinary tract infections, skin and skin structure infections, and severe acne as adjunctive therapy.